A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

References

• De Hert M, Thys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L, . Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519–27.
   PubMed Web of Science ®Google Scholar
• Fadden G, Bebbington P, Kuipers L. The burden of care: The impact of functional psychiatric illness on the patient's family. Br J Psychiatry 1987;150:285–92.
   PubMed Web of Science ®Google Scholar
• Kuipers L. Family burden in schizophrenia: Implications for services. Soc Psychiatry Psychiatr Epidemiol 1993;28:207–10.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, . The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122–9.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
   PubMed Web of Science ®Google Scholar
• Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59:31–7.
   PubMed Web of Science ®Google Scholar
• Grohmann R, Ruther E, Schmidt LG. Unerwunschte Wirkungen von Psychopharmaka. Ergebnisse de AMUP-Studie. Berlin: Springer; 1994.
   Google Scholar
• National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002.
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322–38.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, . Modelling in economic evaluation: An unavoidable fact of life. Health Econ 1997;6:217–27.
   PubMed Web of Science ®Google Scholar
• Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49–56.
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ 2003;326: 472.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, . Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997;154:782–91.
   PubMed Web of Science ®Google Scholar
• Hale A, Azorin J-M, Kasper S, Maier W, Syvalahti E, Van Der Burght M, . Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial. Int J Psychiatr Clin Pract 2000;4:47–54.
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Abbott Study (M92-817). Data on file 1995.
   Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–90.
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765–74.
   PubMed Web of Science ®Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, . The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol 2005;40:707–17.
   PubMed Web of Science ®Google Scholar
• Launois R, Graf von der Schulenburg M, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: A comprehensive model. Int J Psychiatr Clin Pract 1998;2:S79–86.
   PubMedGoogle Scholar
• Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57 Suppl 11:53–60.
   PubMedGoogle Scholar
• Launois R, Almond S, Présenté G, Toumi M. Cost-effectiveness of sertindole versus risperidone, olanzapine or haloperidol: A comprehensive model, sertindole NICE submission 2001. 2001.
   Google Scholar
• Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998;34:61–9.
   PubMed Web of Science ®Google Scholar
• McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, . Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006;189:433–40.
   PubMed Web of Science ®Google Scholar
• De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, . Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: A Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23 Suppl 1:35–47.
   PubMed Web of Science ®Google Scholar
• Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, . Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study. Curr Med Res Opin 2006;22: 2209–19.
   PubMed Web of Science ®Google Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006:CD004578.
   Web of Science ®Google Scholar
• Revicki DA. Cost effectiveness of the newer atypical antipsychotics: A review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001;2:110–7.
   PubMedGoogle Scholar
• Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl 1:49–61.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Miadi-Fargier H, Lancon C, Jasso Mosqueda G, Casadebaig F, Philippe A, . [Cost-effectiveness analysis of schizophrenic patient care settings: Impact of an atypical antipsychotic under long-acting injection formulation]. Encephale 2005;31: 235–46.
   PubMed Web of Science ®Google Scholar
• Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383–9.
   PubMed Web of Science ®Google Scholar
• Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P. Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. J Med Assoc Thai 2005;88:1267–77.
   PubMedGoogle Scholar